Subscribe to RSS
DOI: 10.1055/s-2007-963480
© Georg Thieme Verlag KG Stuttgart · New York
Evidence, Efficacy and Effectiveness of Screening for Colorectal Cancer with Faecal Tests
Publication History
Publication Date:
26 March 2008 (online)

Introduction
Colorectal cancer fulfils the conditions that have been defined for mass screening: it is a major cause of morbidity and mortality in industrialised countries with an estimated number of 213 000 new cases reported in the 15 member states of the European Union in 1996. Despite advances in diagnostic techniques and treatment, the five-year survival rates remain poor. However, colorectal cancer can be cured if detected at an early stage and in certain cases can be prevented by the removal of adenomas. Considerable research efforts have been launched over the last 15 years to evaluate the ability of screening tests’ to decrease colorectal cancer mortality and incidence. Currently, the most simple screening method for colorectal cancer is periodic stool testing for occult blood. The most extensively evaluated test is the Hemoccult II (Smith Kline Diagnostic, California). The purpose of this paper is to consider the evidence for screening for colorectal cancer based on published studies and to present the French screening programme.
References
- 1
Kronborg O, Fenger C, Olsen J. et al .
Randomized study as screening for colorectal cancer with faecal-occult-blood test.
Lancet.
1996;
348
1467-1471
MissingFormLabel
- 2
Hardcastle J D, Chamberlain J O, Robinson M HE. et al .
Randomized controlled trial of faecal-occult-blood screening for colorectal cancer.
Lancet.
1996;
348
1472-1477
MissingFormLabel
- 3
Faivre J, Dancourt V, Lejeune C. et al .
Reduction in colorectal cancer mortality by fecal occult blood screening in a controlled
study in France.
Gastroenterology.
2004;
126
1674-1680
MissingFormLabel
- 4
Mandel J S, Bond J H, Church T R. et al .
Reducing mortality from colorectal cancer by screening for faecal occult blood.
N Engl J Med.
1993;
328
1365-1371
MissingFormLabel
- 5
Jouve J L, Remontet L, Dancourt V. et al .
Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening.
Br J Cancer.
2001;
84
1477-1481
MissingFormLabel
- 6
Bertario L, Spinelli P, Gennari L. et al .
Sensitivity of Hemoccult test for large bowel cancer in high-risk subjects.
Dig Dis Sci.
1988;
33
609-613
MissingFormLabel
- 7
Mandel J S, Church T R, Ederer F. et al .
Colorectal cancer mortality: effectiveness of biennial screening for fecal occult
blood.
J Natl Cancer Inst.
1999;
91
434-437
MissingFormLabel
- 8
Mandel J S, Church T R, Bond J H. et al .
The effect of fecal occult-blood screening on the incidence of colorectal cancer.
N Engl J Med.
2000;
343
1603-1607
MissingFormLabel
- 9
Lang C A, Ransohoff D F.
Facal occult blood screening for colorectal cancer: is mortality reduced by chance
selection for screening colonoscopy?.
JAMA.
1994;
271
1011-1013
MissingFormLabel
- 10
Tazi M A, Faivre J, Dassonville F. et al .
Participation in faecal occult blood screening for colorectal cancer in a well defined
French population : results of five screening rounds from 1988 to 1996.
J Med Screening.
1997;
4
147-151
MissingFormLabel
- 11
Morikawa T, Kato J, Yamaji Y. et al .
A comparison of the immunochemical fecal occult blood test and total colonoscopy in
the asymptomatic population.
Gastroenterology.
2005;
129
422-428
MissingFormLabel
- 12
Guittet L, Bouvier V, Mariotte N. et al .
Comparison of a guaiac-based and an immunochemical fecal occult blood test in screening
for colorectal cancer in a general average-risk population.
Gut.
2007;
56
210-214
MissingFormLabel
- 13
Imperiale T F, Rahsohoff D F, Itzkowitz S H. et al .
Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk
population.
N Engl J Med.
2004;
351
2704-2714
MissingFormLabel
Jean Faivre
Hôpital du Bocage, Hépato-Gastroentérologie
2, Bd Mal de Lattre de Tassigny
21034 Dijon Cedex, France
Phone: ++ 33/3/80 29/37 50
Fax: ++ 33/3/80 29/37 22
Email: jean.faivre@chu-dijon.fr